News Channels

21 Jun 2017 Glenmark Pharmaceuticals Licenses Small Molecule Oncology Compound from APC Therapeutics to Expand Immuno-Oncology Portfolio
21 Jun 2017 Spyryx Biosciences Expands Development Award with Cystic Fibrosis Foundation; Presents Phase 1 Data for SPX-101 at the European Cystic Fibrosis Conference
21 Jun 2017 eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a Novel Immuno-oncology Combination in Microsatellite Stable Colorectal Cancer
21 Jun 2017 Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor
21 Jun 2017 Shire plc: U.S. FDA Approves Mydayis[TM] (Mixed Salts of a Single-Entity Amphetamine Product) - A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older
21 Jun 2017 Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit with Single Agent Imbruvica®▼ (ibrutinib) vs Temsirolimus at First Relapse in Mantle Cell Lymphoma
21 Jun 2017 Synlogic™ Doses First Subject in Phase 1 Trial of Novel Class of Synthetic Biotic™ Medicines
21 Jun 2017 GeNeuro Announces First Patient Treated in Phase 2a Study with GNbAC1 in Type 1 Diabetes
21 Jun 2017 Clovis Oncology’s Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial
21 Jun 2017 Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR707 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Lymphoma
21 Jun 2017 Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA® (pembrolizumab), for the Treatment of HPV-Induced Cervical Cancer
21 Jun 2017 Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine
21 Jun 2017 Ipsen and its partner Exelixis announce independent radiology committee review confirms results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma
21 Jun 2017 twoXAR Announces Preclinical Proof-of-Concept Data on Type 2 Diabetes Candidate
21 Jun 2017 AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Reaches Enrollment Target
21 Jun 2017 Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma
21 Jun 2017 Cell Medica acquires WT1 cancer immunotherapy from Cell and Gene Therapy Catapult
21 Jun 2017 FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients
21 Jun 2017 Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
21 Jun 2017 Merck Ventures Creates New Immuno-Oncology Company iOnctura

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing